SATB2在卵巢黏液性肿瘤中的表达及意义

Abstract
Figure/Table
References (22)
Related Citation (6)

Download: PDF (606 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To determine the expression of special AT-rich sequence binding protein 2 (SATB2) in primary ovarian mucinous carcinoma and metastatic ovarian mucinous adenocarcinoma from colon and rectum, and analyze its significance for clinicopathological diagnosis. Methods Forty-seven cases of patients with primary ovarian mucinous tumors and 48 cases of patients with metastatic ovarian mucinous adenocarcinoma from colon and rectum treated in Cangzhou People′s Hospital of Hebei Province from January 2010 to June 2017 was selected. The expression of SATB2, cytokeratin 7 (CK7), cytokeratin 20 (CK20), caudal-regulated homeobox transcription factor 2 (CDX2) in paraffin specimens of both tumor tissues and ascites was determined by the immunohistochemical method. The expression of SATB2, CK7, CK20 and CDX2 in tumor tissues and ascites was analyzed and compared. The sensitivity and specificity of SATB2 combined with CK7, CK20 and CDX2 for the diagnosis of the origin of ovarian mucinous tumors was analyzed. Results The expression of SATB2 was not related to patient′s age and tumor diameter (P > 0.05), but related to the degree of tissue differentiation, pathological classification, ovarian involvement and clinical stage (P < 0.05). The expression of SATB2, CK7, CK20 and CDX2 was related to the origin of ovarian mucinous tumors (P < 0.05). The sensitivity and specificity of SATB2 combined with CK7 in determining the origin of primary ovarian mucinous tumors and metastatic colorectal mucinous adenocarcinoma were significantly higher than CK20 and CDX2. Conclusion SATB2 is specific in distinguishing tumor origin, it is valuable for clinical pathological diagnosis.

Key words： Special AT-rich sequence binding protein 2 Ovarian mucinous tumor Clinicopathological diagnosis Tumor marker

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Mingyue MA Hongyan LI Xiuqing SUN Jie LIU Xiaoyun

Cite this article:

YANG Mingyue MA Hongyan LI Xiuqing SUN Jie LIU Xiaoyun. Expression and significance of SATB2 in ovarian mucinous tumors[J]. 中国医药导报, 2019, 16(20): 129-132.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I20/129

[1] Siegel RL，Miller KD，Jemal A. Cancer Statistics，2017 [J]. CA Cancer J Clin，2017，67（1）：7-30.
[2] Pascual A，Guerriero S，Rams N，et al. Clinical and ultrasound features of benign，borderline，and malignant invasive mucinous ovarian tumors [J]. Eur J Gynaecol Oncol，2017，38（3）：382-386.
[3] Ziari K，Soleymani E，Alizadeh K. Survival analysis and prognosis for patients with serous and mucinous borderline ovarian tumors：14-year experience from a tertiary center in Iran [J]. Acta Med Iran，2015，53（4）：199-203.
[4] Plaza JA，Mackinnon A，Carrillo L，et al. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma：a clinicopathologic and immunohistochemical study [J]. Am J Dermatopathol 2015，37（11）：809-821.
[5] 刘明娟，郭燕，张翎，等.卵巢癌的CT诊断与鉴别诊断[J].影像诊断与介入放射学，2007（2）：67-71.
[6] 毛卫霞，王永宏.卵巢癌的CT MRI诊断价值比较[J].河北医学，2017，23（11）：1795-1798.
[7] Khunamornpong S，Settakorn J，Sukpan K，et al. Primary ovarian mucinous adenocarcinoma of intestinal type：a clinicopathologic study of 46 cases [J]. Int J Gynecol Pathol， 2014，33（2）：176-185.
[8] Hu A，Li H，Zhang L，et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours：an algorithm combining PAX8 with tumour size and laterality [J]. J Clin Pathol，2015，68（7）：522-528.
[9] Rouzbahman M，Chetty R. Mucinous tumours of appendix and ovary：an overview and evaluation of current practice [J]. J Clin Pathol，2014，67（3）：193-197.
[10] Melamed A，Manning-Geist B，Bregar AJ，et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type [J]. Gynecol Oncol，2017，147（2）：250-256.
[11] McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms [J]. J Clin Pathol，2012，65（7）：596-600.
[12] 苑中甫，史惠蓉，孙红敏，等.原发卵巢癌及卵巢之转移性结肠癌组织中CDX-2与CK7和CK20的表达及其临床意义[J].中华病理学杂志，2007（8）：555-556.
[13] Carleton C，Hoang L，Sah S，et al. A Detailed Immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas [J]. Am J Surg Pathol，2016，40（5）：636-644.
[14] Wang Y，Wang Y，Zheng W. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy [J]. Int J Clin Exp Pathol，2013，6（10）：2121-2128.
[15] Terzi H，Kale E，Kale A，et al. New method：are tumor markers in vaginal-washing fluid significant in the diagnosis of primary ovarian carcinoma? [J]. Eur J Gynaecol Oncol，2015，36（5）：560-563.
[16] Chen XX，Zhang J，Lv CX，et al. Construction and identification of cbfa1 and satb2 co-expression vector [J]. Shanghai Kou Qiang Yi Xue，2011，20（5）：474-478.
[17] 陈虎，周培培，杨蓉，等. SATB2、NANOG和OCT4在口腔鳞癌中的表达及临床意义[J].口腔医学，2015，35（12）：1016-1019.
[18] Tian W，Wang G，Liu Y，et al. The miR-599 promotes non-small cell lung cancer cell invasion via SATB2 [J]. Biochem Biophys Res Commun，2017，485（1）：35-40.
[19] Seong BK，Lau J，Adderley T，et al. SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization [J]. Oncogene，2015，34（27）：3582-3592.
[20] Li Z，Yuan J，Wei L，et al. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors [J]. Int J Clin Exp Pathol，2015，8（6）：7072-7082.
[21] Dragomir A，de Wit M，Johansson C，et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin：results of a pathology-based clinical prospective study [J]. Am J Clin Pathol，2014，141（5）：630-638.
[22] 何兴状，马川，牟辉，等.SATB2基因表达对结直肠癌细胞增殖和转移能力的影响[J].湖南师范大学学报：医学版，2018，15（3）：24-28.